ClinicalTrials.gg
CompletedNCT07123428Updated Aug 14, 2025

Single and Multiple Ascending Doses and Food Effect Study of TRD205 in Healthy Volunteers

A Phase 1 interventional study of TRD205 and Placebo in Healthy, sponsored by Beijing Tide Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of TRD205 after single and multiple doses and to evaluate the effect of food on TRD205 in healthy adult subjects.

Read the detailed description

This study consists of three parts:

  • Single ascending dose study
  • Multiple ascending dose study
  • Food effect study
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Beijing Tide Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who can understand the requirements and potential side effects of the study and voluntarily sign the form.

    • Able to complete the study per protocol and communicate with the investigators.
    • Subjects (and their sexual partners) should voluntarily practice effective per protocol.
    • Healthy subjects aged 18-55 years.
    • Body weight should be ≥ 50 kg for male subjects and ≥ 45 kg for female subjects with a of 18-28 kg/m2.
    • Physical examination and vital sign: normal or are considered by the investigator to be of no clinical significance.
    • No vaccination within 30 days prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Smoking 5 or more cigarettes per day within 3 months before screening.
  • Subjects with an allergic constitution, such as a history of allergy to two or more drugs or food.
  • Subjects who have a history of drug abuse and or alcoholism.
  • Subjects who have had blood donation and/or blood loss ≥ 450 mL wihin 3 months before screening.
  • Subjects who have consumed medications known to alter hepatic drug metabolism enzyme activity within 28 days before screening.
  • Subjects who have taken any other prescription medication, OTC products, vitamins or herbal products within 14 days before screening, except for those exempted by the investigator on a case-by-case basis.
  • Subjects who have eaten special food, such as dragon fruit, mango, pomelo, grapefruit, cranberry and their juice, or had vigorous exercise, or had other factors that may influence the ADME process of drug.
  • Subjects who have concomitant drugs that induce or inhibit , P-gp, Bcrp.
  • Subjects who have consumed products or participated in drug clinical trials within 3 months before taking IP.
  • Subjects who have dysphagia or other gastrointestinal diseases that can influence drug adsorption.
  • Subjects who can not tolerate the standard meal (just for those who participate the food effect study).
  • 12-lead : abnormal results and considered by the investigator to be of clinical significance.
  • Pregnant or lactating women.
  • Laboratory tests: abnormal results and considered by the investigator to be of clinical significance. Or subjects with the diseases of gastrointestinal tract, kidney, liver, nervous system, blood system, endocrinal system, tumor, lung, immunity, mental system, cardiovascular system, cerebral vascular system within 12 months before screening.
  • Positive serological tests for virus (HBV), virus (HCV), (HIV), and treponema pallidum (TP) at screening.
  • Subjects who have had acute disease or concomitant drugs from screening to taking IP.
  • Subjects who have consumed chocolate, Caffeine-containing products or xanthine containing food (such as tea, coffee, colar) within 48 hours beforing taking IP.
  • Subjects who have consumed alcohol-containing products within 48 hours beforing taking IP.
  • Subjects who have a positive urine drug screening test result.
  • Subject who have received surgery within 4 weeks before taking IP.
  • Subject who are not ready to abstain from participation in any other clinical study for the duration of this study and for 30 days or more (as required by the investigator) after completion of the study.
  • Mental or physical disability.
  • Subject cannot tolerate venipuncture blood collection or has a history of sickness at the sight of blood and/or needle.
  • Any reason that, in the opinion of the Investigator, may prevent the subject from participating in the study.
  • Subjects who have the risk factors of torsade de pointes, or a family history of a first-degree relative with short syndrome, long QT syndrome, unexplained sudden death in youth, drowning, or sudden infant death syndrome.
  • Subjects with abnormal and hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia or hypocalcemia as judged by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    TRD205: Single ascending dose (SAD) study

    TRD205: oral, single ascending doses up to 7 doses levels.

    Drug: TRD205

  • Placebo comparator
    Placebo: Single ascending dose (SAD) study

    Placebo: oral, TRD205 placebo in single ascending doses study.

    Drug: Placebo

  • Experimental
    TRD205: Food effect study

    TRD205: oral, just 1 dose under fasted or fed condition for each period.

    Drug: TRD205

  • Placebo comparator
    Placebo: Food effect study

    Placebo: oral, under fasted or fed condition for each period.

    Drug: Placebo

  • Experimental
    Multiple ascending dose (MAD) study

    TRD205: oral, multiple ascending doses up to 4 doses levels. Doses and dosing frequency will be decided based on SAD results.

    Drug: TRD205

Interventions

  • DrugTRD205

    TRD205 tablet

  • DrugPlacebo

    TRD205 placebo tablet

06

What researchers measure

Primary outcomes

  1. Treatment-Related Adverse Events

    The safety and tolerability of TRD205 orally administered once and/or multiple times on an empty stomach in healthy subjects

    Time frame: After a single dose and/or once daily for 10 consecutive doses

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    To evaluate the pharmacokinetic characteristics of a single oral administration of TRD205 in healthy subjects on an empty stomach; To evaluate the pharmacokinetic characteristics of TRD205 orally administered multiple times in healthy subjects; Explore the impact of food on in vivo exposure to TRD205.

    Time frame: After a single dose and/or once daily for 10 consecutive doses

  2. Peak Plasma Concentration(Cmax)

    To evaluate the pharmacokinetic characteristics of a single oral administration of TRD205 in healthy subjects on an empty stomach; To evaluate the pharmacokinetic characteristics of TRD205 orally administered multiple times in healthy subjects; Explore the impact of food on in vivo exposure to TRD205.

    Time frame: After a single dose and/or once daily for 10 consecutive doses

  3. time to peak(Tmax)

    To evaluate the pharmacokinetic characteristics of a single oral administration of TRD205 in healthy subjects on an empty stomach; To evaluate the pharmacokinetic characteristics of TRD205 orally administered multiple times in healthy subjects; Explore the impact of food on in vivo exposure to TRD205.

    Time frame: After a single dose and/or once daily for 10 consecutive doses

  4. Elimination rate constant(Kel)

    To evaluate the pharmacokinetic characteristics of a single oral administration of TRD205 in healthy subjects on an empty stomach; To evaluate the pharmacokinetic characteristics of TRD205 orally administered multiple times in healthy subjects; Explore the impact of food on in vivo exposure to TRD205.

    Time frame: After a single dose and/or once daily for 10 consecutive doses

  5. apparent volume of distribution(Vd)

    To evaluate the pharmacokinetic characteristics of a single oral administration of TRD205 in healthy subjects on an empty stomach; To evaluate the pharmacokinetic characteristics of TRD205 orally administered multiple times in healthy subjects; Explore the impact of food on in vivo exposure to TRD205.

    Time frame: After a single dose and/or once daily for 10 consecutive doses

  6. elimination half life(T1/2)

    To evaluate the pharmacokinetic characteristics of a single oral administration of TRD205 in healthy subjects on an empty stomach; To evaluate the pharmacokinetic characteristics of TRD205 orally administered multiple times in healthy subjects; Explore the impact of food on in vivo exposure to TRD205.

    Time frame: After a single dose and/or once daily for 10 consecutive doses

  7. Mean retention time(MRT)

    To evaluate the pharmacokinetic characteristics of a single oral administration of TRD205 in healthy subjects on an empty stomach; To evaluate the pharmacokinetic characteristics of TRD205 orally administered multiple times in healthy subjects; Explore the impact of food on in vivo exposure to TRD205.

    Time frame: After a single dose and/or once daily for 10 consecutive doses

07

Study locations

1 site
  • The first hospital of Jilin University
    Changchun, Jilin 130021, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Nov 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Aug 14, 2025
StartActual
Jan 26, 2024
Primary completionActual
Nov 27, 2024
CompletionActual
Feb 27, 2025
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07123428
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Jan 26, 2024
Primary completion
Nov 27, 2024
Completion
Feb 27, 2025
Last update
Aug 14, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRD205

Start the discussion